With approximately one third of all current FDA-approved drugs targeting GPCRs, Verily/Sosei ... well as where he thinks AI’s use in drug discovery and development might lead the industry.

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the ...

Class Biology with Agile AI and Chemistry Automation for Rapid Discovery of Better Molecules for Highly Valuable G Protein-Coupled Receptor (GPCR) TargetsMENLO PARK, Calif., May 21, 2025 (GLOBE ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

SOUTH SAN FFRANCISCO, CA, USA and BAGSVAERD, Denmark I May 14, 2025 I Septerna, Inc. (Nasdaq: SEPN) and Novo Nordisk today announced an exclusive global ...

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...

2,3 According to Novo Nordisk, GPCRs are the largest and most varied group of cell surface receptors, playing key roles in regulating functions across nearly every organ system in the body. They are ...

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...

Danish drug manufacturer Novo Nordisk is partnering with California-based biotech Septerna to develop the latest pills to ...